Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)

Jonsson Comprehensive Cancer Center

Status and phase: Completed; Early Phase 1

Conditions: Prostate Carcinoma

Treatments: Drug: Gallium Ga 68-labeled PSMA-11; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Biospecimen Collection; Dietary Supplement: Monosodium Glutamate

Study type: Interventional

Funder types: Other

Identifiers

NCT04282824

18-001776 (Other Identifier)

NCI-2019-04437 (Registry Identifier)

Details and patient eligibility

About

This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells. 68GA-PSMA-11 is an imaging radioactive drug that can target this molecule in tissues for imaging and therapy of prostate cancer. Food substances, such as monosodium glutamate, may reduce salivary gland uptake of 68GA-PSMA-11. Ultimately, giving MSG may reduce potential harm and injury to the salivary glands in patients with prostate cancer treated with PSMA-targeted molecular radiotherapy.

Full description

PRIMARY OBJECTIVE:

I. To determine the effect of monosodium glutamate (MSG) administration (glutamate supplementation) on the salivary gland uptake of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11).

SECONDARY OBJECTIVES:

I. To determine the effect of MSG administration on renal 68Ga-PSMA-11 uptake. II. To determine the effect of MSG administration on tumor 68Ga-PSMA-11 uptake. III. To determine if 68GA-PSMA-11 is excreted in the saliva. IV. Safety of MSG administration both oral ingestion and oral-salivary stimulation.

OUTLINE: Patients are randomized to 1 of 2 arms.

Arm I: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) and undergo a positron emission tomography (PET)/computed tomography (CT) scan on day 1. Within 2 weeks (days 2-14), patients receive MSG orally (PO) over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Arm II: Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Enrollment: 14 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient volunteer to undergo 2 PSMA PET/CT scans within 14 days

• Histopathologically proven prostate cancer (PCa)

• PSMA PET/CT indicated for :

  • Initial staging before definitive therapy
  • Biochemical recurrence localization
  • Metastatic disease re-staging

• Ability to understand a written informed consent document and the willingness to sign it

• Ability to ingest 300 mL of fluid across 10 minute period

Exclusion criteria

• Prior salivary gland surgery or radiation therapy
• Prior history or current salivary gland disease
• Unable to lie flat, still or tolerate a PET scan
• Unable to follow the salivary flow stimuli administration regimen
• Unable to follow the glutamate supplementation administration regimens
• Asthma
• Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg, or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension under medication are eligible
• Sodium/salt restricted diet due to other medical conditions
• History of severe asthma that has led to hospitalizations or emergency room visits
• History of severe contraindications to MSG consumption including severe headaches, migraines or other intolerance
• Change to treatment administered between time of baseline scan and MSG scan

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

14 participants in 2 patient groups

Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)

Experimental group

Description:

8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Treatment:

Dietary Supplement: Monosodium Glutamate

Procedure: Biospecimen Collection

Procedure: Positron Emission Tomography

Procedure: Computed Tomography

Drug: Gallium Ga 68-labeled PSMA-11

Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)

Experimental group

Description:

8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Treatment:

Dietary Supplement: Monosodium Glutamate

Procedure: Biospecimen Collection

Procedure: Positron Emission Tomography

Procedure: Computed Tomography

Drug: Gallium Ga 68-labeled PSMA-11